Fig. 3
From: NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth
SiRNA-NAP1L1 reduces cell proliferation in vitro. A RT-qPCR showed that NAP1L1 mRNA expression was upregulated after the breast cancer cells were transfected with siRNA-NAP1L1 lentivirus compared to NC siRNA-control. B Western blot analysis showed that the protein level of NAP1L1 was upregulated after the breast cancer cells were transfected with siRNA-NAP1L1 lentivirus compared to NC siRNA-control. C MTT assays showed that the inhibition of NAP1L1 reduces cell proliferation in vitro in breast cancer MCF-7 and MDA-MB-231 cell lines. D Downregulation of NAP1L1 suppressed the EdU staining of breast cancer cells in vitro (scale bar: 200 μm). Scrambled siRNA was as an control for siRNA. The data are presented as mean ± s.d. from three independent experiments. *P < 0.05 vs. control; **P < 0.01; ***P < 0.001